<?xml version="1.0"?>
<oembed><version>1.0</version><provider_name>Orbital</provider_name><provider_url>https://www.orbital-itn.eu</provider_url><author_name>hammad</author_name><author_url>https://www.orbital-itn.eu/author/hammad/</author_url><title>Project 6: Generation &amp; Characterisation of Sustained Release Ocular Implants for Neuroprotective Drug Efficacy - Orbital</title><type>rich</type><width>600</width><height>338</height><html>&lt;blockquote class="wp-embedded-content"&gt;&lt;a href="https://www.orbital-itn.eu/projects/generation-characterisation-of-sustained-release-ocular-implants-for-neuroprotective-drug-efficacy/"&gt;Project 6: Generation &amp; Characterisation of Sustained Release Ocular Implants for Neuroprotective Drug Efficacy&lt;/a&gt;&lt;/blockquote&gt;
&lt;script type='text/javascript'&gt;
&lt;!--//--&gt;&lt;![CDATA[//&gt;&lt;!--
		/*! This file is auto-generated */
		!function(d,l){"use strict";var e=!1,o=!1;if(l.querySelector)if(d.addEventListener)e=!0;if(d.wp=d.wp||{},!d.wp.receiveEmbedMessage)if(d.wp.receiveEmbedMessage=function(e){var t=e.data;if(t)if(t.secret||t.message||t.value)if(!/[^a-zA-Z0-9]/.test(t.secret)){var r,a,i,s,n,o=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),c=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]');for(r=0;r&lt;c.length;r++)c[r].style.display="none";for(r=0;r&lt;o.length;r++)if(a=o[r],e.source===a.contentWindow){if(a.removeAttribute("style"),"height"===t.message){if(1e3&lt;(i=parseInt(t.value,10)))i=1e3;else if(~~i&lt;200)i=200;a.height=i}if("link"===t.message)if(s=l.createElement("a"),n=l.createElement("a"),s.href=a.getAttribute("src"),n.href=t.value,n.host===s.host)if(l.activeElement===a)d.top.location.href=t.value}}},e)d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",t,!1),d.addEventListener("load",t,!1);function t(){if(!o){o=!0;var e,t,r,a,i=-1!==navigator.appVersion.indexOf("MSIE 10"),s=!!navigator.userAgent.match(/Trident.*rv:11\./),n=l.querySelectorAll("iframe.wp-embedded-content");for(t=0;t&lt;n.length;t++){if(!(r=n[t]).getAttribute("data-secret"))a=Math.random().toString(36).substr(2,10),r.src+="#?secret="+a,r.setAttribute("data-secret",a);if(i||s)(e=r.cloneNode(!0)).removeAttribute("security"),r.parentNode.replaceChild(e,r)}}}}(window,document);
//--&gt;&lt;!]]&gt;
&lt;/script&gt;&lt;iframe sandbox="allow-scripts" security="restricted" src="https://www.orbital-itn.eu/projects/generation-characterisation-of-sustained-release-ocular-implants-for-neuroprotective-drug-efficacy/embed/" width="600" height="338" title="&#x201C;Project 6: Generation &amp; Characterisation of Sustained Release Ocular Implants for Neuroprotective Drug Efficacy&#x201D; &#x2014; Orbital" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"&gt;&lt;/iframe&gt;</html><description>There is an unmet clinical need to develop effective treatments for blindness due to retinal dysfunction. Notably, in Europe, 0.7 million citizens are considered blind and an additional 34 million citizens affected by vision loss. This translates to 123 million workdays lost per year and an annual economic cost to European society of &#x20AC;7.1 billion. &hellip; Read More</description></oembed>
